PT Meprofarm
↗Bandung, Indonesia
PT Meprofarm is a prominent Indonesian pharmaceutical company established in 1973. The company specializes in the research, development, and manufacturing of a wide range of healthcare products, including ethical (prescription) drugs, over-the-counter (OTC) medicines, and nutritional supplements. It is recognized as one of the top pharmaceutical manufacturers in Indonesia, operating high-tech facilities that comply with international standards.
The company maintains a strong focus on therapeutic areas such as anti-infectives, cardiovascular health, metabolic disorders, and respiratory medicine. Meprofarm operates a large-scale manufacturing plant in Bandung, West Java, which is certified for Good Manufacturing Practices (GMP/CPOB) and ISO standards. They are a key player in the Southeast Asian generic and branded-generic market, often partnering with international firms for local distribution and manufacturing.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$100M-$500M
Founded:1973
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Oral Solids, Liquids, Injectables
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Meprofarm (Singapore) Pte Ltd
Key Partnerships:Various international pharmaceutical firms for toll manufacturing and local licensing in the Indonesian market.
COMPETITION
Position:Leader
Competitors:Kalbe Farma, Dexa Medica, Kimia Farma, Sanbe Farma, Phapros
LEADERSHIP
Key Executives:
Cynthia Santoso - Director
LINKS
Website:meprofarm.co.id
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with PT Meprofarm. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.